{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T08:50:27Z","timestamp":1782204627783,"version":"3.54.5"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Heart Journal"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ihj.2026.04.013","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T06:58:08Z","timestamp":1776668288000},"page":"164-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of early initiation of PCSK9I monoclonal antibodies after acute coronary syndrome"],"prefix":"10.1016","volume":"78","author":[{"given":"Pravin K.","family":"Goel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kala Jeetender","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Thachathodiyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Guleria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam","family":"Sasidharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ihj.2026.04.013_bib1","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.1161\/CIR.0000000000001328","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American college of cardiology\/american heart association joint committee on clinical practice guidelines","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2026.04.013_bib2","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.18203\/2320-6012.ijrms20222373","article-title":"Recent trends in the pattern and long-term management strategy of patients diagnosed with acute coronary syndrome in India: an observational study","volume":"10","author":"Nayak","year":"2022","journal-title":"Int J Res Med Scie"},{"key":"10.1016\/j.ihj.2026.04.013_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ihj.2018.12.005","article-title":"Short- and long-term follow-up of antithrombotic management patterns in patients hospitalized with acute coronary syndrome: indian subgroup of EPICOR Asia study","volume":"71","author":"Sawhney","year":"2019","journal-title":"Indian Heart J"},{"key":"10.1016\/j.ihj.2026.04.013_bib4","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1093\/eurheartj\/ehae885","article-title":"Incident heart failure and recurrent coronary events following acute myocardial infarction","volume":"46","author":"Butler","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2026.04.013_bib5","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/eurjhf\/hfq194","article-title":"Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction","volume":"13","author":"Thune","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ihj.2026.04.013_bib6","first-page":"939","volume":"11","author":"Krychtiuk","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.ihj.2026.04.013_bib7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40119-025-00397-6","article-title":"Cardiovascular outcomes of early LDL-C goal achievement in patients with very-high-risk ASCVD","volume":"14","author":"Kim","year":"2025","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.ihj.2026.04.013_bib8","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1161\/CIRCRESAHA.114.302805","article-title":"Lipoproteins as biomarkers and therapeutic targets in the setting of acute coronary syndrome","volume":"114","author":"Rosenson","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.ihj.2026.04.013_bib9","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jacc.2020.07.033","article-title":"Low-density lipoprotein cholesterol and adverse cardiovascular events after percutaneous coronary intervention","volume":"76","author":"Sud","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2026.04.013_bib10","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJM200009283431303","article-title":"Multiple complex coronary plaques in patients with acute myocardial infarction","volume":"343","author":"Goldstein","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2026.04.013_bib11","article-title":"Evaluating LDL-C control in Indian acute coronary syndrome (ACS) patients- A retrospective real-world study LDL-C control in ACS","volume":"19","author":"Jain","year":"2023","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"key":"10.1016\/j.ihj.2026.04.013_bib12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4103\/jpcs.jpcs_58_21","article-title":"Clinical and angiographic profile of acute coronary syndrome patients (<40 years) and short-term prognosis: a cross-sectional study","volume":"7","author":"Varun","year":"2021","journal-title":"J Pract Cardiovasc Sci"},{"key":"10.1016\/j.ihj.2026.04.013_bib13","series-title":"Cholesterol Treatment Trialists (CTT) Collaboration","year":"2016"},{"key":"10.1016\/j.ihj.2026.04.013_bib14","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2026.04.013_bib15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4093\/dmj.2017.0081","article-title":"Serum levels of PCSK9 are associated with coronary angiographic severity in patients with acute coronary syndrome","volume":"42","author":"Bae","year":"2018","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.ihj.2026.04.013_bib16","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.cca.2018.04.040","article-title":"PCSK9: a potential regulator of apoE\/apoER2 against inflammation in atherosclerosis?","volume":"483","author":"Bai","year":"2018","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.ihj.2026.04.013_bib17","first-page":"1","article-title":"Targeting proprotein convertase subtilisin\/kexin type 9 (PCSK9): from bench to bedside","volume":"9","author":"Bao","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.ihj.2026.04.013_bib18","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1186\/s12872-024-04057-w","article-title":"Early administration of proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis","volume":"24","author":"Hosseini","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.ihj.2026.04.013_bib21","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3904\/kjim.2024.080","article-title":"Efficacy of single-dose evolocumab injection in early-phase acute myocardial infarction: a retrospective single-center study","volume":"39","author":"Kim","year":"2024","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.ihj.2026.04.013_bib22","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.3390\/ijms22063144","article-title":"Pleiotropic effects of PCSK-9 inhibitors","volume":"22","author":"Basiak","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ihj.2026.04.013_bib23","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40262-017-0620-7","article-title":"Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor","volume":"57","author":"Kasichayanula","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ihj.2026.04.013_bib24","first-page":"204","article-title":"Feasibility of short-term aggressive lipid-lowering therapy with the PCSK9 antibody in acute coronary syndrome","volume":"10","author":"Yamashita","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1016\/j.ihj.2026.04.013_bib25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/eurheartj\/ehs219","article-title":"Presentation, management, and outcomes of 25 748 acute coronary syndrome admissions in Kerala, India: results from the Kerala ACS registry","volume":"34","author":"Mohanan","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2026.04.013_bib26","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2026.04.013_bib27","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1093\/eurheartj\/ehx450","article-title":"Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the cholesterol treatment trialists collaboration","volume":"39","author":"Ference","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2026.04.013_bib28","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/CIRCULATIONAHA.118.034309","article-title":"Clinical benefit of evolocumab by severity and extent of coronary artery disease","volume":"138","author":"Sabatine","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2026.04.013_bib29","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2026.04.013_bib30","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","article-title":"Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial","volume":"107","author":"Ballantyne","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2026.04.013_bib31","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2026.04.013_bib32","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2026.04.013_bib33","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ihj.2026.04.013_bib34","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2026.04.013_bib35","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2026.04.013_bib36","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ihj.2026.04.013_bib37","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","article-title":"Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS)","volume":"74","author":"Koskinas","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2026.04.013_bib38","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1161\/CIRCULATIONAHA.120.046320","article-title":"Effect of evolocumab on atherogenic lipoproteins during the Peri- and early postinfarction period: a placebo-controlled, randomized trial","volume":"142","author":"Leucker","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2026.04.013_bib39","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC, Cardiovasc Imaging"},{"key":"10.1016\/j.ihj.2026.04.013_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jacc.2025.09.123","article-title":"TCT-68 early initiation of PCSK9 inhibitors in acute STEMI: safety and efficacy outcomes from the EARLY-STEMI trial","volume":"86","author":"Ali","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2026.04.013_bib41","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005367","article-title":"Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia","volume":"6","author":"Toth","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ihj.2026.04.013_bib42","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.amjcard.2023.10.043","article-title":"Early initiation of PCSK9 inhibitor therapy versus placebo in patients with acute coronary syndrome: a systematic review and meta-analysis","volume":"213","author":"Justino","year":"2024","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ihj.2026.04.013_bib43","doi-asserted-by":"crossref","first-page":"e888","DOI":"10.4244\/EIJ-D-22-00735","article-title":"Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial","volume":"18","author":"Mehta","year":"2022","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ihj.2026.04.013_bib44","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity Statin therapy on coronary atherosclerosis in patients with acute myocardial infarction","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ihj.2026.04.013_bib45","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/FJC.0000000000000706","article-title":"Alirocumab in acute myocardial infarction: results from the Virginia commonwealth university alirocumab response trial (VCU-AlirocRT)","volume":"74","author":"Trankle","year":"2019","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ihj.2026.04.013_bib46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.athplu.2025.09.005","article-title":"Inclisiran for fast-track lipid-lowering treatment early after an acute coronary syndrome: a pilot study","volume":"62","author":"Lupi","year":"2025","journal-title":"Atheroscler Plus"},{"key":"10.1016\/j.ihj.2026.04.013_bib47","doi-asserted-by":"crossref","DOI":"10.1161\/circ.150.suppl_1.4139074","article-title":"Abstract 4139074: clinical characteristics and treatment of high-risk cardiovascular patients without prior myocardial infarction or stroke: VESALIUS-REAL - results from US","volume":"150","author":"Chan","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2026.04.013_bib48","doi-asserted-by":"crossref","first-page":"244","DOI":"10.23736\/S0031-0808.22.04777-2","article-title":"Lipid-lowering treatment up to one year after acute coronary syndrome: guidance from a French expert panel for the implementation of guidelines in practice","volume":"65","author":"Sabouret","year":"2023","journal-title":"Panminerva Med"},{"key":"10.1016\/j.ihj.2026.04.013_bib49","article-title":"Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: a frequentist network meta-analysis","volume":"98","author":"Zhao","year":"2019","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.ihj.2026.04.013_bib50","doi-asserted-by":"crossref","first-page":"270","DOI":"10.31083\/j.rcm2409270","article-title":"Early addition of evolocumab to statin treatment in patients with acute coronary syndrome and multivessel disease undergoing percutaneous coronary intervention","volume":"24","author":"Zhang","year":"2023","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.ihj.2026.04.013_bib51","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/ehjqcco\/qcae099","article-title":"Treatment with PCSK9 monoclonal antibodies is associated with discontinuation of oral lipid lowering therapy","volume":"11","author":"Engebretsen","year":"2025","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.ihj.2026.04.013_bib52","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eprac.2024.11.006","article-title":"Highlights of the 2025 American association of clinical endocrinology clinical practice guideline on pharmacologic management of adults with dyslipidemia","volume":"31","author":"Correa","year":"2025","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ihj.2026.04.013_bib53","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.eprac.2024.09.016","article-title":"American association of clinical endocrinology clinical practice guideline on pharmacologic management of adults with dyslipidemia","volume":"31","author":"Patel","year":"2025","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ihj.2026.04.013_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020821","article-title":"A cross-sectional study of the microeconomic impact of cardiovascular disease hospitalization in four low- and middle-income countries","volume":"6","author":"Huffman","year":"2011","journal-title":"PLoS One"}],"container-title":["Indian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483226000751?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483226000751?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T08:22:55Z","timestamp":1782202975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019483226000751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0019483226000751"],"URL":"https:\/\/doi.org\/10.1016\/j.ihj.2026.04.013","relation":{},"ISSN":["0019-4832"],"issn-type":[{"value":"0019-4832","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of early initiation of PCSK9I monoclonal antibodies after acute coronary syndrome","name":"articletitle","label":"Article Title"},{"value":"Indian Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ihj.2026.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Cardiological Society of India. Published by Elsevier, a division of RELX India, Pvt. Ltd.","name":"copyright","label":"Copyright"}]}}